Sequential design of phase II-III cancer trials

Statistics in Medicine

Volumn 31, Issue 18, 2012, Pages 1944-1960

  Lai, Tze Leung ^a   Lavori, Philip W ^a   Shih, Mei Chiung ^a,b  

^a STANFORD UNIVERSITY   (United States)

^b VA Cooperative Studies Program   (United States)

Author keywords

Generalized likelihood ratio statistics; Group sequential clinical trials; Phase II III designs; Survival analysis

Indexed keywords

ANTINEOPLASTIC AGENT; C MET PROTEIN INHIBITOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANALYTICAL ERROR; ARTICLE; BAYES THEOREM; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL RESEARCH; CLUSTER ANALYSIS; COMPARATIVE EFFECTIVENESS; DRUG RESPONSE; DRUG TREATMENT FAILURE; FEASIBILITY STUDY; HUMAN; PARAMETRIC TEST; PATIENT CARE; PROGRESSION FREE SURVIVAL; RANDOMIZATION; SEQUENTIAL ANALYSIS; STATISTICAL MODEL; STUDY DESIGN; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; COMPUTER SIMULATION; DISEASE-FREE SURVIVAL; HUMANS; MALE; MODELS, STATISTICAL; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RESEARCH DESIGN;

EID: 84863993425     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.5346     Document Type: Article

References (25)

1. El-Maraghi RH, Eisenhauer EA. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III. Journal of Clinical Oncology 2008; 26:1346-1354. DOI: 10.1200/JCO.2007.13.5913.
2. Chan JK, Ueda SM, Sugiyama VE, Starve CD, Shin JY, Monk BJ, Sikic BI, Osann K, Kapp DS. Analysis of phase studies on targeted agents and subsequent phase III trials: what are the predictors for success? Journal of Clinical Oncology 2008; 26:1511-1518. DOI: 10.1200/JCO.2007.14.8874.
3. Simon R. Optimal two-stage designs for Phase II clinical trials. Controlled Clinical Trials 1989; 10:1-10.
4. Jung S-H, Lee T, Kim K, George SL. Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine 2004; 23:561-569. DOI: 10.1002/sim.1600.
5. Banerjee A, Tsiatis AA. Adaptive two-stage designs in phase II clinical trials. Statistics in Medicine 2006; 25:3382-3395. DOI: 10.1002/sim.2501.
6. Vickers AJ, Ballen V, Scher HI. Setting the bar in Phase III trials: the use of historical data for determining "Go/No Go" decision for definitive Phase II trials. Clinical Cancer Research 2007; 13:972-976. DOI: 10.1158/1078-0432. CCR-06-0909.
7. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews 2004; 3:711-715. DOI: 10.1038/nrd1470.
8. Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. European Journal of Cancer 2009; 45:275-280. DOI: 10.1016/j.ejca.2008.10.029.
9. Rubinstein L, Crowley J, Ivy P, LeBlanc M, Sargent D. Randomized phase II designs. Clinical Cancer Research 2009; 15:1883-1890. DOI: 10.1158/1078-0432.CCR-08-2031.
10. Wittes J, Brittain E. The role of internal pilot studies in increasing efficiency of clinical trials. Statistics in Medicine 1990; 9:65-72. DOI: 10.1002/sim.4780090113.
11. Bartroff J, Lai TL. Efficient adaptive designs with mid-course sample size adjustment in clinical trials. Statistics in Medicine 2008; 27:1593-1611. DOI: 10.1002/sim.3201.
12. Thall PF, Simon R, Ellenberg SS. Two-stage selection and testing designs for comparative clinical trials. Biometrika 1988; 75:303-310.
13. Ellenberg SS, Eisenberger MA. An efficient design for Phase III studies of combination chemotherapies (with discussion). Cancer Treatment Reports 1985; 69:1147-1154.
14. Inoue LYT, Thall PF, Berry DA. Seamlessly expanding a randomized Phase II trial to Phase III. Biometrics 2002; 58:823-831.
15. Huang X, Ning J, Li Y, Estay E, Issa J-P, Berry DA. Using short-term response information to facilitate adaptive randomization for survival clinical trials. Statistics in Medicine 2009; 28:1680-1689. DOI: 10.1002/sim.3578.
16. Thall PF. A review of phase 2-3 clinical trial designs. Lifetime Data Analysis 2008; 14:37-53.
17. Jennison C, Turnbull BW. Efficient group sequential designs when there are several effect sizes under consideration. Statistics in Medicine 2006; 25:917-932. DOI: 10.1002/sim.2251.
18. Lai TL, Shih MC. Power, sample size and adaptation considerations in the design of group sequential clinical trials. Biometrika 2004; 91:507-528.
19. Gu M, Lai TL. Repeated significance testing with censored rank statistics in interim analysis of clinical trials. Statistica Sinica 1998; 8:411-428.
20. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine 2004; 351:1502-1512.
21. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine 2004; 351:1513-1520.
22. Smith MR, Kabbinavar F, Saad F et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Journal of Clinical Oncology 2005; 23:2918-2925. DOI: 10.1200/JCO.2005.01.529.
23. Jennison C, Turnbull BW. Group Sequential Methods with Applications to Clinical Trials. Chapman and Hall/CRC: London, 2000.
24. Siegmund DO. Sequential Analysis: Tests and Confidence Intervals. Springer: New York, 1985.
25. Bilias Y, Gu M, Ying Z. Towards a general asymptotic theory for Cox model with staggered entry. Annals of Statistics 1997; 25:662-682.